The Timing of Surgical Ligation for Patent Ductus Arteriosus Is Associated with Neonatal Morbidity in Extremely Preterm Infants Born at 23-25 Weeks of Gestation

The purpose of this study was to evaluate prognostic factors associated with surgical ligation for patent ductus arteriosus (PDA) in extremely preterm infants born at the limits of viability. Ninety infants who were born at 23-25 weeks of gestation and who received surgical ligation were included and their cases were retrospectively reviewed. Infants were classified into two different groups: survivors with no major morbidity (N), and non-survivors or survivors with any major morbidity (M). Clinical characteristics were compared between the groups. Possible prognostic factors were derived from this comparison and further tested by logistic regression analysis. The mean gestational age and the mean birth weight of M were significantly lower than those of N. Notably, the mean postnatal age at time of ligation in N was significantly later than that of the other group (17 ± 12 vs 11 ± 8 days in N and M, respectively). An adjusted analysis showed that delayed ligation ( > 2 weeks) was uniquely associated with a significantly decreased risk for mortality or composite morbidity after surgical ligation (OR, 0.105; 95% CI, 0.012-0.928). In conclusion, delayed surgical ligation for PDA ( > 2 weeks) is associated with decreased mortality or morbidities in extremely preterm infants born at 23-25 weeks of gestation.

Keywords: Ductus Arteriosus, Patent; Ligation; Indomethacin; Ibuprofen

INTRODUCTION

Patent ductus arteriosus (PDA) is a common problem encountered in the early neonatal period, particularly in preterm infants. However, controversy regarding the treatment of PDA still exists. Of greatest concern is the treatment of PDA in extremely preterm infants “born at the limits of viability” because 1) the rate of spontaneous ductal closure is extremely low (1); 2) the response rate to pharmacologic treatment is very low as well (1, 2); and 3) they are prone to develop hemodynamically significant PDA with cardiopulmonary compromise (3). For these reasons, surgical ligation is frequently performed despite the surgical risk and complications. However, there is a paucity of data concerning the factors affecting neonatal outcomes after surgical ligation in extremely preterm infants. The purpose of this study was to investigate the prognostic factors associated with surgical ligation for PDA in infants born at 23 to 25 weeks of gestation.

MATERIALS AND METHODS

We retrospectively reviewed the medical records of all infants with a gestational age of 23-25 weeks. They were born and admitted to the neonatal intensive care unit (NICU) at Samsung Medical Center from January 2005 to December 2010.

Study population

A flow diagram of the study population is shown in Fig. 1. A total of 165 extremely preterm infants was reviewed and 51 out of 165 infants were excluded because they showed 1) no visible PDA (n = 21); 2) a very small PDA with a minimal shunt (PDA of no hemodynamic significance) on echocardiogram (n = 7); or 3) congenital anomalies, birth asphyxia, or mortality within the first 48 hr (n = 23).

A total of 114 infants had hemodynamically significant PDA. Of 114 infants, 50 infants were treated with primary surgical ligation because pharmacologic treatment was contraindicated. The remaining 64 infants were treated with either indomethacin (n = 57) or ibuprofen (n = 7). Of these 64 infants, 40 infants eventually underwent surgical ligation. Therefore, a total of 90 infants ultimately received surgical ligation (primarily or after pharmacologic treatment failure) and were included in this study.

Evaluation and management of PDA

A routine echocardiogram was performed on all infants within
two weeks of birth as indicated by their clinical status. If the infants were confirmed to have left-to-right flow or bidirectional flow with a dominant left-to-right shunt through the PDA, and if there were any findings suggesting congestive heart failure, including tachycardia, hypotension, decreased urination, intolerable enteral feeding, cardiomegaly, etc., they were regarded to have hemodynamically significant PDA, and pharmacologic treatment was initiated as soon as possible (4). Indomethacin or ibuprofen was administered intravenously as a pharmacologic treatment. Prophylactic indomethacin was not used, i.e. all pharmacologic treatments were performed as a rescue therapy.

Surgical ligation was indicated if 1) one or two cycles of cyclooxygenase inhibitors failed to close the PDA, and the infants still had symptoms of congestive heart failure (n = 40); or, 2) if there were any contraindications to pharmacologic treatment, including thrombocytopenia (platelet count < 50,000/µL), renal dysfunction (urinary output of 0.5 mL/kg/h or less within 24 hr before surgery, plus serum creatinine ≥ 2.0 mg/dL), or necrotizing enterocolitis (NEC)-like symptoms (abdominal distention, bluish abdominal color, or feeding intolerance with greenish gastric residue) (n = 50).

An analysis of prognostic factors after surgical ligation

To analyze the prognostic factors associated with surgical ligation, infants were classified into two groups according to outcome: survivors with no major morbidity (N), and survivors with any type of major morbidity or non-survivors (M). Major morbidities included intraventricular hemorrhage (≥ grade III), cystic periventricular leukomalacia, moderate-to-severe bronchopulmonary dysplasia, and necrotizing enterocolitis (≥ stage II). Intraventricular hemorrhage (IVH) was diagnosed by brain ultrasonography and graded by Papile’s classification system (5). Bronchopulmonary dysplasia (BPD) was defined by the Jobe and Bancalari criteria of Ehrenkranz et al. (6). Necrotizing enterocolitis (NEC) was staged according to modified Bell’s criteria (7) (Table 1).

Demographic characteristics, including gestational age, birth weight, small-for-gestational-age status, sex, Apgar score at 1 and 5 min, in vitro fertilization, pregnancy-induced hypertension, pathologically confirmed chorioamnionitis, and antenatal glucocorticoid administration, were compared between the two groups (Table 2). Gestational age was assessed by calculating from the first day of the mother’s last menstrual period or by estimation from prenatal ultrasonography. Clinical characteristics associated with the evaluation or the management of PDA, including the use of pharmacologic treatment prior to surgery, mean postnatal age at the time of the first diagnosis of PDA, mean postnatal age at the time of surgical ligation, mean duration of exposure to PDA, and PDA size at the time of initial detection and surgical ligation were compared between the groups. Preoperative clinical conditions, including the incidence of pulmonary hemorrhage, hypotension, fraction of inspired oxygen (FiO2), and urine output within 24 hr prior to surgery were also compared between the groups. Hypotension was defined as when an infant’s mean blood pressure measured less than the number of gestational age in weeks, with a need for inotropic support within 24 hr before surgery. Indications of ligation were also compared between the groups.

Unadjusted and adjusted analysis for the risk of composite morbidity

Possible prognostic factors derived from the preceding analysis were examined by unadjusted and adjusted logistic regression analysis. Odds ratios (OR) with 95% confidence intervals (95% CI) for the risk of composite morbidity were calculated and are shown in Table 3. A composite morbidity was defined as the occurrence of mortality or at least one of the major morbidities previously noted.

Statistical methods

The comparisons of demographic and clinical characteristics between the two groups were performed using chi-square tests or Fisher’s exact tests for categorical variables and Student’s t-test for continuous variables. A binary logistic regression was used for the unadjusted and adjusted analysis. All analyses were
Table 2. A comparison of demographic and clinical characteristics between groups according to the occurrence of mortality or morbidity

| Characteristics                          | N (n = 21)     | M (n = 69)     | P value |
|------------------------------------------|----------------|----------------|---------|
| Demographic factors                      |                |                |         |
| Gestational age (weeks)                  | 24.9 ± 0.9     | 24.3 ± 0.8     | 0.007   |
| Birth weight (g)                         | 731 ± 85       | 661 ± 126      | 0.020   |
| Small for gestational age, No. (%)       | 2 (9.5)        | 7 (10.1)       | 1.000   |
| Male, No. (%)                            | 8 (38.1)       | 33 (47.8)      | 0.465   |
| Apgar score at 1 min                     | 5 ± 2          | 4 ± 1          | 0.502   |
| Apgar score at 5 min                     | 7 ± 2          | 7 ± 1          | 0.559   |
| In vitro fertilization, No. (%)          | 8 (38.1)       | 15 (21.7)      | 0.158   |
| Maternal hypertension, No. (%)           | 2 (9.5)        | 3 (4.3)        | 0.331   |
| Chorioamnionitis, No. (%)                | 12 (57.1)      | 32 (46.4)      | 0.459   |
| Antenatal steroid, No. (%)               | 19 (90.5)      | 64 (92.8)      | 0.733   |
| Clinical characteristics associated with PDA |                  |                |         |
| Pharmacologic treatment, No. (%)         | 13 (61.9)      | 27 (39.1)      | 0.082   |
| Mean age at initial detection of PDA, days | 6.0 ± 5.1      | 6.5 ± 3.8      | 0.106   |
| Mean age at surgical ligation, days       | 17 ± 12        | 11 ± 8         | 0.039   |
| Mean duration of exposure to PDA, days    | 11 ± 10        | 5 ± 4          | 0.186   |
| PDA size at time of initial detection (mm)| 2.2 ± 1.2      | 2.3 ± 0.7      | 0.147   |
| Pre-ligation clinical conditions          |                |                |         |
| Pulmonary hemorrhage, No. (%)            | 2 (9.5)        | 12 (17.4)      | 0.384   |
| Hypotension, No. (%)                     | 2 (9.5)        | 7 (10.1)       | 0.934   |
| Mean FiO<sub>2</sub> prior to ligation    | 0.24 ± 0.05    | 0.30 ± 0.12    | 0.016   |
| Urine output (mL/kg/hr)                  | 2.4 ± 1.5      | 2.3 ± 1.2      | 0.732   |
| Surgical ligation                        |                |                |         |
| Primary ligation (contraindications of pharmacologic treatment) | 8 (38.1)       | 42 (60.9)      | 0.082   |
| - Renal dysfunction, No. (%)             | 2 (9.5)        | 9 (13.0)       | 0.666   |
| - Thrombocytopenia, No. (%)              | 2 (9.5)        | 9 (13.0)       | 0.666   |
| - NEC-like symptoms, No. (%)             | 4 (19.0)       | 24 (34.8)      | 0.173   |
| Secondary ligation (failure of pharmacologic treatment) | 13 (61.9)      | 27 (39.1)      | 0.082   |

N, survivors with no morbidity; M, non-survivors or survivors with any type of major morbidity; FiO<sub>2</sub>, fraction of inspired oxygen.

Table 3. Unadjusted and adjusted odds ratios for the risk of composite morbidity by gestational age, birth weight, the use of preoperative pharmacologic treatment, and the timing of surgical ligation

| Parameters                          | Unadjusted | Adjusted |               |               |
|-------------------------------------|------------|----------|---------------|---------------|
|                                     | OR  | 95% CI | P value  | OR  | 95% CI | P value  |
| Gestational age                      |     |        |          |     |        |          |
| 23 weeks                            | 4.800| 1.187-19.415 | 0.028 | 1.686| 0.248-11.461 | 0.593 |
| 24 weeks                            | 2.500| 0.797-7.839 | 0.116 | 2.502| 0.608-10.302 | 0.204 |
| 25 weeks                            | 1.000| (reference)|        | 1.000| (reference)|        |
| Birth weight                         |     |        |          |     |        |          |
| < 600 g                              | 11.294| 1.290-98.899 | 0.029 | 7.846| 0.547-112.484 | 0.129 |
| 600-749 g                            | 1.059| 0.359-3.121 | 0.917 | 0.917| 0.221-3.803 | 0.905 |
| ≥ 750 g                              | 1.000| (reference)|        | 1.000| (reference)|        |
| Mean FiO<sub>2</sub> prior to ligation|     |        |          |     |        |          |
| FiO<sub>2</sub> > 0.21 (per every 0.1 increase) | 2.150| 0.941-4.914 | 0.069 | 2.012| 0.863-4.692 | 0.106 |
| FiO<sub>2</sub> of 0.21               | 1.000| (reference)|        | 1.000| (reference)|        |
| Age at time of ligation              |     |        |          |     |        |          |
| > 2 weeks                            | 0.114| 0.114-0.908 | 0.40 | 0.105| 0.012-0.928 | 0.043 |
| ≤ 2 weeks                            | 1.000| (reference)|        | 1.000| (reference)|        |

performed using Predictive Analytics SoftWare Statistics version 20.0 (SPSS Inc., Chicago, IL, USA).

Ethics statement
This study was approved by the Samsung Medical Center institutional review board (IRB No. 2013-02-087). The need for informed consent was waived by the board because of the retrospective nature of this study.

RESULTS
The outcomes after surgical ligation are shown in Table 1. Fourteen (15.6%) infants died and 69 (76.7%) infants had composite morbidity in this study. A comparison between N (n = 21), and M (n = 69) is presented in Table 2. The gestational ages were different between the groups, with the mean gestational age of M being lower than that of N (24.3 ± 0.8 weeks in M vs 24.9 ± 0.9 weeks in N). The mean birth weight of M was significantly
lower than that of N (661 ± 126 g in M and 731 ± 85 g in N).

The rate of pharmacologic treatment in M was lower than that in N (39.1% in M vs 61.9% in N); however, it did not reach statistical significance. Notably, the timing of surgical ligation showed a significant difference between the groups. The mean postnatal age at the time of ligation in M was lower than that of N (11 ± 8 days in M vs 17 ± 12 in N). Additionally, mean FiO₂ within the 24 hr prior to ligation was significantly higher in M compared to that of N (0.24 ± 0.05 in N vs 0.30 ± 0.12 in M). Otherwise, there was no difference between the groups with respect to prenatal and postnatal clinical characteristics.

Gestational age, birth weight, mean FiO₂ prior to ligation, and the timing of surgical ligation were selected as possible prognostic factors and were included in further analysis (Table 3). In the unadjusted analysis, a gestational age of 23 weeks, a birth weight of less than 600 g, and mean FiO₂ greater than 0.21 before ligation were each respectively associated with an increased risk of composite morbidity (OR of 4.800, 11.294, and 2.150, respectively), whereas delayed ligation (after 2 weeks) was associated with a decreased risk of composite morbidity (OR of 0.114 with 95% CI of 0.114-0.908). In the adjusted analysis, the increases in odds ratios at a gestational age of 23 weeks, a birth weight of less than 600 g, or mean FiO₂ greater than 0.21 prior to ligation did not reach statistical significance. However, delayed ligation (after 2 weeks) still showed a significant decrease in the risk for composite morbidity over early ligation (within 2 weeks) (OR of 0.105 with 95% CI of 0.012-0.928) after adjusting for gestational age, birth weight, and mean FiO₂ greater than 0.21 prior to ligation.

**DISCUSSION**

According to Koch et al., the spontaneous ductal closure rate and the complete response rate to pharmacologic treatment in infants with a gestational age of less than 25 weeks are approximately 2.5% and 9%, respectively (1). Our data showed them to be 5.8% and 12.5%, respectively, for infants with a gestational age of 23-25 weeks. Jhaveri et al. reported that 81% of infants born at 24-25 weeks gestation underwent surgical ligation, and our data showed that 79% of infants born at 23-25 weeks gestation required surgical ligation (3). Despite the high rate of surgical ligation in these infants, little is known about the prognostic factors associated with surgical ligation. The optimal timing of surgical ligation is also undetermined. Here, we found that delayed (> 2 weeks) ligation was associated with a decreased risk for composite morbidity.

To prove that timing determines outcome, it is important to analyze the status of the PDA and any preoperative clinical conditions that might interfere with the outcome, because in early surgery, infants might be in a riskier condition that resulted in them receiving an earlier intervention. Despite the prevailing concerns of persistent opening of the ductus arteriosus, our results showed that delayed ligation and prolonged exposure to persistent PDA were not detrimental. Similarly, how early the PDA was diagnosed did not appear to matter, because the timing of the initial detection of PDA did not differ between the groups. The size of the PDA also did not appear to affect neonatal outcome. Preoperative cardiovascular and renal conditions indicated by the occurrence of pulmonary hemorrhage, hypertension, and oliguria showed no difference between the groups, and were also not likely to act as confounders. Of note, the FiO₂ prior to surgery showed a significant difference between the groups. To exclude the possibility that preoperative respiratory conditions altered the results, univariate and multivariate analyses were performed. A FiO₂ greater than 0.21 within 24 hr prior to ligation was associated with an increased risk of composite morbidity on univariate analysis (OR of 2.150 per every 0.1 increase of FiO₂ with 95% CI of 0.941-4.914) with a nearly significant P value (P = 0.069). However, the multivariate analysis revealed that it was not significant after controlling for gestational age, birth weight, and delayed ligation (OR of 2.012 per every 0.1 increase of FiO₂ with 95% CI of 0.863-4.692, and P value of 0.106).

Ligation was indicated when pharmacologic treatment was contraindicated (primary ligation) or failed to close PDA (secondary ligation). As the timing of primary ligation was earlier than that of secondary ligation (10 ± 6 days vs 16 ± 9 days, P = 0.002), contraindications could contribute to early ligation, leading to worse outcomes. Comparisons between the two groups with regard to contraindications of pharmacologic treatment showed that the incidence of renal dysfunction, thrombocytopenia, and NEC-like symptoms did not vary. Because primary ligation was performed more frequently in M than in N with a nearly significant difference (P = 0.082), it was necessary to determine whether pharmacologic treatment per se had a protective effect on composite morbidity. A univariate and multivariate analysis showed that the use of pharmacologic treatment did not alter the risk of composite morbidity (OR of 0.699 with 95% CI of 0.263-1.863 and OR of 0.672 with 95% CI of 0.205-2.202, respectively) (8).

According to the result of the multivariate analysis, delayed ligation is uniquely associated with increased risk of composite morbidity. It is, of course, inappropriate to assume that worse neonatal outcomes were entirely caused by early PDA ligation, given the limitations of this study that stem from its retrospective nature. This study simply highlights the necessity of a prospective study to clarify the causal relationship between the timing of ligation and neonatal morbidity.

A few previous studies have evaluated the optimal timing of surgical ligation in preterm infants. However, they have reported conflicting results (9-13). Moreover, these studies did not target extremely preterm infants at the limits of viability, although these infants undergo surgical ligation the most frequently and
under the riskiest conditions. This was a single center study with a relatively large number of extremely preterm infants and also the first study to examine the prognostic factors associated with surgical ligation in such infants.

Because of the recent acknowledgement of the physiology of PDA and the adverse effects on various organ systems of treatment (14-17), most current studies have focused on delayed treatment and a more conservative approach for preterm infants (18-21). Considering the surgical complications and hemodynamic instability after ligation (22-24), we also believe that early aggressive intervention could be detrimental to these tiny infants. Although it would be difficult to reduce the rate of surgical intervention, our data suggest that it appears to be advantageous to avoid surgical ligation in the early, vulnerable period.

In conclusion, delayed surgical ligation of PDA is associated with decreased neonatal morbidity in extremely preterm infants born at 23-25 weeks of gestation. Further well-designed, randomized, controlled clinical studies and experimental studies will be needed to confirm the detrimental effects of surgical ligation in the early period of life and its precise pathophysiology in extremely preterm infants.

DISCLOSURE

The authors have no conflicts of interest to disclose.

ORCID

Se In Sung http://orcid.org/0000-0002-8717-6142
Soo Young Choi http://orcid.org/0000-0001-5541-4479
Jae Hyun Park http://orcid.org/0000-0001-8953-3695
Myung Sook Lee http://orcid.org/0000-0002-2148-7394
Hye Soo Yoo http://orcid.org/0000-0001-7230-1839
So Yoon Ahn http://orcid.org/0000-0002-1821-3173
Yun Sil Chang http://orcid.org/0000-0001-9201-2938
Won Soon Park http://orcid.org/0000-0002-8245-4692

REFERENCES

1. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117: 1113-21.
2. Alexander F, Chiu L, Kroh M, Hammel J, Moore J. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 2009; 44: 112-7.
3. Jalil MB, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 2010; 157: 381-7, 387.e1.
4. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92: F424-7.
5. Burstein J, Papile LA, Burstein R. Intraventricular hemorrhage and hydrocephalus in premature newborns: a prospective study with CT. AJR Am J Roentgenol 1979; 132: 631-5.
6. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K. National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 1353-60.
7. Walsh MC, Kliegman RM, Fanaroff AA. Necrotizing enterocolitis: a practitioner’s perspective. Pediatr Rev 1988; 9: 219-26.
8. Malviya MN, Ohlsson A, Shah SS. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2008; (1): CD003951.
9. Mosalli R, Alfaleh K, Paes B. Role of prophylactic surgical ligation of patent ductus arteriosus in extremely low birth weight infants: systematic review and implications for clinical practice. Ann Pediatr Cardiol 2009; 2: 120-6.
10. Robie DK, Waltrip T, Garcia-Prats JA, Pokorny WJ, Jaksic T. Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight? J Pediatr Surg 1996; 31: 1134-7.
11. Hsiao CC, Wung JT, Tsao LY, Chang WC. Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants. J Formos Med Assoc 2009; 108: 72-7.
12. Julaard L, Sarrue B, Rakza T, Magnenant E, Warembourg H, Storme L. Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants. Ann Thorac Surg 2006; 81: 231-4.
13. vida VL, Lago P, Salvatori S, Boccuzzo G, Pudalino MA, Milanesi O, Speggiorni S, Stellin G. Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants? Ann Thorac Surg 2009; 87: 1509-15.
14. Waleh N, McCurnin DC, Yoder BA, Shaull PW, Clyman RL. Patent ductus arteriosus ligation alters pulmonary gene expression in preterm baboons. Pediatr Res 2011; 69: 212-6.
15. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125: 1020-30.
16. Antonucci R, Bassareo P; Zaffanello M, Pusceddu M, Fanos V. Patent ductus arteriosus in the preterm infant: new insights into pathogenesis and clinical management. J Matern Fetal Neonatal Med 2010; 23: 34-7.
17. Sehgal A, Ramsden CA, McNamara PJ. Indomethacin impairs coronary perfusion in infants with hemodynamically significant ductus arteriosus. Neonatology 2012; 101: 20-7.
18. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30: 241-52.
19. Benitz WE. Learning to live with patency of the ductus arteriosus in preterm infants. J Perinatol 2011; 31: 542-8.
20. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007; 92: F498-502.
21. Vanhaesebrouck S, Zonnenberg J, Vandervoort P; Bruneel E, Van Hoes tenberge MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed 2007; 92: F244-7.
22. McNamara PJ, Stewart L, Shivananda SP, Stephens D, Sehgal A. Patent ductus arteriosus ligation is associated with impaired left ventricular systolic performance in premature infants weighing less than 1000 g. J
23. Noori S, Friedlich P, Seri I, Wong P. Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants. J Pediatr 2007; 150: 597-602.

24. Teixeira LS, Shivananda SP, Stephens D, Van Arsdell G, McNamara PJ. Postoperative cardiorespiratory instability following ligation of the preterm ductus arteriosus is related to early need for intervention. J Perinatal 2008; 28: 803-10.